Literature DB >> 28496867

Atrial Fibrillation - A Common Ground for Neurology and Cardiology.

Fawzi Abukhalil1, Aakash Bodhit1, Peter Y Cai1,2, Saeed Ansari2,3, Spandana Thenkabail4, Sarah Ganji1, Pradeepan Saravanapavan1, Chandana Chandra Shekhar1, Michael F Waters1, Thomas M Beaver5, Vishnumurthy Shushrutha Hedna1.   

Abstract

Atrial fibrillation (AF) has a huge impact on clinical stroke because it is the primary cause of cardio-embolism, which constitutes ~20% of all strokes. As a result, there is a great need to explore safer and more effective primary and secondary prophylactic agents. In this article, we discuss the overlapping issues pertaining to AF from both a neurology and cardiology standpoint. We focus on the dynamic interplay of neurovascular and cardiovascular diseases in relation to AF, traditional and novel risk factors for AF leading to stroke, impact of AF on cognitive decline, and current upstream medical and surgical options for embolism prophylaxis.

Entities:  

Year:  2013        PMID： 28496867      PMCID： PMC5153225          DOI： 10.4022/jafib.550

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN： 1941-6911


  86 in total

1.  Video-assisted bilateral pulmonary vein isolation and left atrial appendage exclusion for atrial fibrillation.

Authors:  Randall K Wolf; E William Schneeberger; Robert Osterday; Doug Miller; Walter Merrill; John B Flege; A Marc Gillinov
Journal:  J Thorac Cardiovasc Surg       Date:  2005-09       Impact factor: 5.209

2.  The effect of walking on fitness, fatness and resting blood pressure: a meta-analysis of randomised, controlled trials.

Authors:  Marie H Murphy; Alan M Nevill; Elaine M Murtagh; Roger L Holder
Journal:  Prev Med       Date:  2006-12-24       Impact factor: 4.018

3.  European ancestry as a risk factor for atrial fibrillation in African Americans.

Authors:  Gregory M Marcus; Alvaro Alonso; Carmen A Peralta; Guillaume Lettre; Eric Vittinghoff; Steven A Lubitz; Ervin R Fox; Yamini S Levitzky; Reena Mehra; Kathleen F Kerr; Rajat Deo; Nona Sotoodehnia; Meggie Akylbekova; Patrick T Ellinor; Dina N Paltoo; Elsayed Z Soliman; Emelia J Benjamin; Susan R Heckbert
Journal:  Circulation       Date:  2010-11-16       Impact factor: 29.690

4.  Pitx2c and Nkx2-5 are required for the formation and identity of the pulmonary myocardium.

Authors:  Mathilda T M Mommersteeg; Nigel A Brown; Owen W J Prall; Corrie de Gier-de Vries; Richard P Harvey; Antoon F M Moorman; Vincent M Christoffels
Journal:  Circ Res       Date:  2007-09-06       Impact factor: 17.367

5.  Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation.

Authors:  Apoor S Gami; Dave O Hodge; Regina M Herges; Eric J Olson; Jiri Nykodym; Tomas Kara; Virend K Somers
Journal:  J Am Coll Cardiol       Date:  2007-01-22       Impact factor: 24.094

6.  Place of dabigatran in contemporary pharmacotherapy.

Authors:  John G Gums
Journal:  Pharmacotherapy       Date:  2011-04       Impact factor: 4.705

Review 7.  Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion?

Authors:  Alan G Dawson; Sanjay Asopa; Joel Dunning
Journal:  Interact Cardiovasc Thorac Surg       Date:  2009-11-26

8.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

9.  N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study.

Authors:  Kristen K Patton; Patrick T Ellinor; Susan R Heckbert; Robert H Christenson; Christopher DeFilippi; John S Gottdiener; Richard A Kronmal
Journal:  Circulation       Date:  2009-10-19       Impact factor: 29.690

10.  Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women.

Authors:  David Conen; Usha B Tedrow; Bruce A Koplan; Robert J Glynn; Julie E Buring; Christine M Albert
Journal:  Circulation       Date:  2009-04-13       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.